$1.54
2.22% today
Nasdaq, Apr 02, 10:00 pm CET
ISIN
US64132R1077
Symbol
MTVA
Sector
Industry

NeuroBo Pharmaceuticals Inc Stock price

$1.54
+0.09 6.21% 1M
-1.15 42.75% 6M
-0.49 24.14% YTD
-2.39 60.81% 1Y
-214.48 99.29% 3Y
-3,423.28 99.96% 5Y
-55,198.46 100.00% 10Y
Nasdaq, Closing price Wed, Apr 02 2025
-0.04 2.22%
ISIN
US64132R1077
Symbol
MTVA
Sector
Industry

Key metrics

Market capitalization $13.63m
Enterprise Value $-2.25m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.09
P/B ratio (TTM) P/B ratio 1.72
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-28.81m
Free Cash Flow (TTM) Free Cash Flow $-24.72m
Cash position $16.02m
EPS (TTM) EPS $-4.32
P/E forward negative
Short interest 2.20%
Show more

Is NeuroBo Pharmaceuticals Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,807 stocks worldwide.

NeuroBo Pharmaceuticals Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

3 Analysts have issued a NeuroBo Pharmaceuticals Inc forecast:

3x Buy
100%

Analyst Opinions

3 Analysts have issued a NeuroBo Pharmaceuticals Inc forecast:

Buy
100%

Financial data from NeuroBo Pharmaceuticals Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
- -
-
100%
- Direct Costs 0.02 0.02
100% 100%
-
-0.02 -0.02
100% 100%
-
- Selling and Administrative Expenses 7.22 7.22
7% 7%
-
- Research and Development Expense 22 22
135% 135%
-
-29 -29
81% 81%
-
- Depreciation and Amortization 0.02 0.02
100% 100%
-
EBIT (Operating Income) EBIT -29 -29
81% 81%
-
Net Profit -28 -28
121% 121%
-

In millions USD.

Don't miss a Thing! We will send you all news about NeuroBo Pharmaceuticals Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

NeuroBo Pharmaceuticals Inc Stock News

Neutral
PRNewsWire
13 days ago
Top-Line Data From MAD Part  2  of the Phase 1 Trial of DA-1726 Expected in April of 2025 Announced Positive Top-Line 16-Week Results from the Phase 2a Trial of DA-1241 for the Treatment of MASH, in December, Demonstrating Direct Hepatic Action in Addition to Its Glucose Lowering Effect $16.0 Million in Cash at  End of Fourth Quarter E xpected to Fund the Company Into the Third Quarter of 2025 ...
Neutral
PRNewsWire
5 months ago
New Nasdaq Ticker Symbol will be MTVA CAMBRIDGE, Mass. , Nov. 18, 2024 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced a strategic realignment, ahead of important clinical milestones, with a corporate name change to "MetaVia Inc.," which will be effective on November 29, 2024 (...
Neutral
PRNewsWire
5 months ago
CAMBRIDGE, Mass. , Nov. 13, 2024 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced participation in the following investor conferences in November: November 14: Life Science Virtual Investor Forum.
More NeuroBo Pharmaceuticals Inc News

Company Profile

NeuroBo Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing novel pharmaceuticals to treat neurodegenerative disorders. The company was founded on October 30, 2014 and is headquartered in Boston, MA.

Head office United States
CEO Hyung-Heon Kim
Employees 9
Founded 2014
Website www.neurobopharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today